Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapyAmyé Tevaarwerk, Joseph A. Sparano|Cancer|2012Cited by 193
A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III <i>PIK3CA</i> -Mutant ER-Positive and HER2-Negative Breast CancerX. Cynthia, Matthew J. Ellis, Matthew P. Goetz et al.|Clinical Cancer Research|2017Cited by 74